How To Find Plasmapheresis Clinics

What Is Plasmapheresis?

Plasmapheresis — from the Greek plasma (something formed) and aphaeresis (taking away) — is a procedure in which blood is drawn from a patient, the liquid portion (plasma) is separated from the blood cells, processed or replaced, and then returned to the body. Think of it as a "wash" for your blood.

Your plasma is the yellowish liquid that carries proteins, antibodies, clotting factors, hormones, and yes — also potential disease-causing substances like autoantibodies, inflammatory cytokines, immune complexes, toxins, and pathogenic proteins. In conditions where these harmful substances accumulate, plasmapheresis offers a way to physically remove them.

The umbrella term apheresis refers to any procedure that separates and removes specific blood components. Within that category, the most common approaches are:

• Therapeutic Plasma Exchange (TPE) — removes and replaces most of the plasma with albumin or donor plasma
• Double Filtration Plasmapheresis (DFPP) — uses two-stage filtration to selectively remove large harmful molecules while preserving albumin
• INUSpheresis® — a proprietary DFPP-based system that filters plasma through specialized membranes to remove a broad spectrum of pathogenic substances
• Immunoadsorption (IA) — selectively binds and removes specific antibody classes
• H.E.L.P. Apheresis — a heparin-mediated precipitation method targeting lipoproteins and fibrinogen

What Can It Be Used For?

Plasmapheresis has decades of established use in medicine. The American Society for Apheresis (ASFA) maintains guidelines that rank conditions by evidence quality, from Category I (strongly indicated) to Category IV (insufficient evidence). Established uses include:

For Long COVID and COVID vaccine adverse events, the theory of benefit is compelling: both conditions are associated with persistent autoantibodies, elevated inflammatory cytokines, fibrin amyloid microclots, and aberrant immune activation — all of which are in principle removable via apheresis. Research is active but still maturing (see the Research section below).

Understanding the distinction between these two approaches is essential before contacting any clinic, because most US clinics only offer one of them.

Key Clinical Point A 2026 systematic review in Hemodialysis International described DFPP as an advanced extracorporeal blood purification technique that selectively removes pathogenic macromolecules based on molecular weight — using a two-step filtration process to retain beneficial plasma components such as albumin, while eliminating harmful substances, thereby reducing the need for exogenous plasma replacement.

 

What Is INUSpheresis®?

INUSpheresis® is a proprietary double-filtration apheresis system developed in Germany by INUS Medical Devices. It uses a specialized two-membrane filtration process (using TKM58 filter technology) to remove a remarkably broad range of substances from blood plasma without discarding the patient's own albumin.

The substances that INUSpheresis is designed to remove include:

• Autoantibodies (including neurotransmitter receptor antibodies — a key target in Long COVID)
• Inflammatory cytokines (IL-1β, IL-6, CRP)
• Oxidized LDLs and lipoproteins
• Environmental and chemical toxins
• Fibrinogen and clotting-related proteins
• Immune complexes and large immunoglobulins (especially IgM)
• Pathogens and viral fragments (including potentially spike protein remnants)

A landmark 2023 study published in Molecular Psychiatry treated 27 Long COVID patients with INUSpheresis and found significant reductions in neurotransmitter autoantibodies, lipids, and inflammatory markers. Notably, a 70% reduction in fibrinogen was observed, and erythrocyte rouleaux formation (a hallmark of microclot pathology) largely disappeared after treatment. This directly addresses two key pathological features seen in Long COVID blood: autoantibody burden and abnormal clotting patterns.

INUSpheresis or DFPP vs. Standard US TPE — The Key Difference

INUSpheresis is currently performed routinely in Germany, Austria, Switzerland, and Japan — and is being pursued for FDA approval in the United States (see below).

What Is H.E.L.P. Apheresis?

H.E.L.P. stands for Heparin-mediated Extracorporeal LDL Precipitation. It is a distinct apheresis modality that works by precipitating lipoproteins out of the plasma using heparin at an acidic pH. The precipitate — which includes LDL cholesterol, Lp(a), fibrinogen, and some inflammatory proteins — is then filtered out, and the treated plasma is returned.

H.E.L.P. apheresis is FDA-approved in the United States specifically for familial hypercholesterolemia and elevated Lp(a) when diet and drug therapy have failed. It is not the same as INUSpheresis, and it is not designed to target the autoantibody/cytokine burden seen in Long COVID — though some practitioners have explored crossover applications given its fibrinogen-lowering properties.

MaxWell Clinic's branded H.O.P.E. Protocol (Habitat Optimizing Plasma Exchange) is a different acronym — a proprietary customized TPE approach — not H.E.L.P. apheresis. Be aware of terminology differences when contacting clinics.

How to Access Plasmapheresis Through Insurance

Insurance coverage for plasmapheresis in the United States is a complex and often frustrating landscape. Here is a frank breakdown:

When Insurance Will Typically Cover TPE

Most major insurers (including Aetna, Cigna, Blue Cross) follow American Society for Apheresis (ASFA) Category I and II guidelines for coverage. Conditions that are generally covered when medically documented include:

• Thrombotic Thrombocytopenic Purpura (TTP)
• Guillain-Barré Syndrome
• Myasthenia Gravis (acute, medication-refractory)
• CIDP (Chronic Inflammatory Demyelinating Polyneuropathy)
• Goodpasture Syndrome / anti-GBM disease
• ANCA-associated vasculitis with severe renal involvement

When Coverage Is Denied (And What To Do)

For Long COVID, vaccine adverse events, ME/CFS, and longevity applications, expect denial as the default response from commercial insurers. These indications are generally classified as investigational or experimental. However, denial is not the end of the road:

• Appeal with documentation. Have your physician document your specific diagnosis using established diagnostic codes. Frame the request around a recognized underlying condition (autoimmune disease, severe neurological impairment) rather than "Long COVID" alone if possible.
• Medicare may be more favorable. Medicare has historically been more willing to cover TPE for autoimmune conditions — even ones considered experimental by private insurers — when the treating physician documents medical necessity and other treatments have failed.
• Get a physician's letter of medical necessity. This is non-negotiable for any appeal. The letter should cite specific ASFA guidelines, reference published studies, and document your treatment history showing other modalities have been tried.
• Prior authorization is required. Even for covered indications, most insurers require prior authorization before the procedure. Your treating physician's office must initiate this process.
• Employer-sponsored plans vary widely. Large self-insured employer plans have more flexibility. A benefits specialist or patient advocate can sometimes negotiate coverage that a standard plan would deny.

What Is Almost Never Covered

Cash-pay longevity and anti-aging applications, INUSpheresis (not FDA approved), and DFPP for Long COVID are not covered by insurance at this time. These are self-pay procedures at all current US clinics offering them.

Where to Get Plasmapheresis in the USA: Clinic Directory

Clinics Working to Bring INUSpheresis to the USA

INUSpheresis — the same double-filtration blood purification being performed in Germany and Japan — is not yet widely available in the United States. However, two clinics are actively working to change that, with announcements with arrival in 2027:

Going international - For patients unable to wait for US availability: Several clinics across Europe offer HELP apheresis and INUSpheresis, including Cypress and Germany at approximately 10,000-22,000 euros.  DFPP combined with stem cell growth factor therapy is currently available in Japan, at approximately $60,000 for 3–4 sessions.  Blood testing can be arranged remotely before travel to assess candidacy. This is a significant undertaking and should be discussed thoroughly with a knowledgeable physician before pursuing.

⚠️ Why Provider Expertise Is Critical — Do Not Skip This Section

Therapeutic plasma exchange carries a genuine risk profile that demands experienced clinical oversight:

• Hypocalcemia — citrate used as anticoagulant binds calcium; improper monitoring can cause cardiac arrhythmias
• Hypotension — large-volume plasma shifts can cause serious blood pressure drops
• Allergic reactions — to albumin, fresh frozen plasma, or replacement fluids
• Infection risk — vascular access (especially central lines) carries infection risk
• Coagulopathy — removal of clotting factors during TPE can increase bleeding risk
• Immunoglobulin depletion — excessive or poorly spaced sessions can leave patients immunocompromised
• Wrong protocol for condition — choosing standard TPE when DFPP is indicated (or vice versa) may reduce efficacy or increase potential for adverse events

Beyond safety, expertise matters enormously for outcomes. A physician well-versed in apheresis for Long COVID will understand the timing of sessions, optimal replacement fluid formulations, concurrent supportive therapies, how to interpret your biomarkers before and after treatment, and how to escalate care if you respond poorly.

Key Research: Apheresis for Long COVID & Vaccine Adverse Events

The following studies represent the current landscape of evidence for apheresis in post-COVID conditions and vaccine injury. This is an emerging field — the science is advancing rapidly, and large randomized controlled trials are still underway. What follows is a summary of the most relevant published work to date.

Final Note: Advocacy and Access

For Long COVID and vaccine injury patients, the path to apheresis treatment in the US is largely managed by specialists nationwide. Cash pay options are currently expensive, time-consuming, and largely outside the insurance system. The landscape is changing rapidly,  with Extension Health's INUSpheresis clinical trial coming soon, representing a potential watershed moment for US access.

If you are pursuing this treatment, the most effective steps are:

(1) find a physician knowledgeable in apheresis and post-COVID pathophysiology before booking a procedure,

(2) get comprehensive baseline labs including autoantibody panels, inflammatory markers, and fibrinogen, and

(3) document everything meticulously for both clinical tracking and potential insurance appeals in the future.

You are not alone in navigating this. Patient communities including REACT19 are actively holding patient-led discussions as this treatment's benefits and risks continue to evolve with time. Please email us at info@react19.org to connect with a community to discuss further.